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with cardiovascular disease and conditions such as metabolic 
syndrome and type 2 diabetes, which have increased cardiovascular 
risk.5 Whether or not low testosterone is merely a consequence of the 
underlying disease process or promotes the atherosclerotic progression 
is currently not fully understood. he major question that needs to be 
understood is whether or not testosterone ameliorates and/or stabilizes 
the atherosclerotic plaque. It is important to recognize that the efects 
of testosterone will depend on normalization of levels for an individual 
as beneits may not occur if there is undertreatment or overtreatment 
as is well recognized for many hormones, for example, thyroxine 
INTRODUCTION
Evidence from basic science and clinical studies has demonstrated 
that testosterone does afect the cardiovascular system in health and 
disease. he efects of testosterone may be diferent between normal 
physiological conditions compared with pathophysiological states. 
Testosterone has been shown to inluence vascular reactivity with 
diferences between vascular beds and tissue‑speciic systemic blood 
supply.1 Furthermore, testosterone can afect peripheral vascular 
resistance, cardiac electrophysiology, and cardiac output.2–4 Several 
epidemiological studies have shown an association of low testosterone 
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Testosterone deficiency is common in men with cardiovascular disease (CVD), and randomized placebo-controlled trials (RCTs) have 
reported beneficial effects of testosterone therapy on exercise-induced cardiac ischemia in chronic stable angina, functional exercise 
capacity, maximum oxygen consumption during exercise (VO
2max
) and muscle strength in chronic heart failure (CHF), shortening 
of the Q-T interval, and improvement of some cardiovascular risk factors. Testosterone deficiency is associated with an adverse CV 
risk profile and mortality. Clinical and scientific studies have provided mechanistic evidence to support and explain the findings 
of the RCTs. Testosterone is a rapid-onset arterial vasodilator within the coronary circulation and other vascular beds including 
the pulmonary vasculature and can reduce the overall peripheral systemic vascular resistance. Evidence has demonstrated that 
testosterone mediates this effect on vascular reactivity through calcium channel blockade (L-calcium channel) and stimulates 
potassium channel opening by direct nongenomic mechanisms. Testosterone also stimulates repolarization of cardiac myocytes 
by stimulating the ultra-rapid potassium channel-operated current. Testosterone improves cardiac output, functional exercise 
capacity, VO
2max
 and vagally mediated arterial baroreceptor cardiac reflex sensitivity in CHF, and other mechanisms. Independent 
of the benefit of testosterone on cardiac function, testosterone substitution may also increase skeletal muscle glucose metabolism 
and enhance muscular strength, both factors that could contribute to the improvement in functional exercise capacity may include 
improved glucose metabolism and muscle strength. Testosterone improves metabolic CV risk factors including body composition, 
insulin resistance, and hypercholesterolemia by improving both glucose utilization and lipid metabolism by a combination of 
genomic and nongenomic actions of glucose uptake and utilization expression of the insulin receptor, glucose transporters, and 
expression on regulatory enzymes of key metabolic pathways. The effect on high-density lipoprotein-cholesterol (HDL-C) differs 
between studies in that it has been found to fall, rise, or have no change in levels. Testosterone replacement can suppress the 
levels of circulating pro-inflammatory cytokines and stimulate the production of interleukin-10 (IL-10) which has anti-inflammatory 
and anti-atherogenic actions in men with CVD. No effect on C-reactive protein has been detected. No adverse effects on clotting 
factors have been detected. RCTs have not clearly demonstrated any significant evidence that testosterone improves or adversely 
affects the surrogate markers of atherosclerosis such as reduction in carotid intima thickness or coronary calcium deposition. 
Any effect of testosterone on prevention or amelioration of atherosclerosis is likely to occur over years as shown in statin therapy 
trials and not months as used in testosterone RCTs. The weight of evidence from long-term epidemiological studies supports a 
protective effect as evidenced by a reduction in major adverse CV events (MACEs) and mortality in studies which have treated men 
with testosterone deficiency. No RCT where testosterone has been replaced to the normal healthy range has reported a significant 
benefit or adverse effect on MACE nor has any recent meta-analysis.
Asian Journal of Andrology (2018) 20, 1–11; doi: 10.4103/aja.aja_6_18; published online: 9 February 2018
Keywords: cardiovascular; testosterone; testosterone replacement
1Robert Hague Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK; 2Academic Unit of Diabetes, Endocrinology and 
Metabolism, Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK; 3Biomedical Research Centre, Sheffield Hallam University, 
Sheffield, UK.
Correspondence: Prof. TH Jones (hugh.jones@nhs.net or t.h.jones@sheffield.ac.uk) 
Received: 07 November 2017; Accepted: 12 January 2018
Open Access
M
a
le
 E
n
d
o
cr
in
o
lo
g
y
[Downloaded free from http://www.ajandrology.com on Tuesday, February 27, 2018, IP: 143.52.49.85]
Asian Journal of Andrology 
Testosterone and the cardiovascular system 
TH Jones and DM Kelly
2
replacement in hypothyroidism. his review will examine and discuss 
the current state of knowledge of the physiological mechanisms from 
randomized clinical trials  (RCTs) to try and provide a considered 
analysis of current knowledge.
Prior to embarking on reviewing the available evidence, it is 
important to understand the biological parameters that contribute 
to normal androgenization. he actions of testosterone are mainly 
mediated by androgen receptor (AR) which binds to speciic androgen 
response elements in the promoter regions of target genes. However, 
it has become increasingly evident that testosterone in common 
with other steroid hormones also has rapid‑onset nongenomic 
actions, possibly AR‑independent genomic mechanisms and efects 
mediated by its conversion to other active hormones – estradiol and 
dihydrotestosterone.
he AR CAG repeat polymorphism, which ranges from 9 to 35 
repeats, is associated with receptor sensitivity, with the lower number of 
repeats having the greatest sensitivity.6 he importance of AR sensitivity 
is relected in signiicant impact on the phenotype. Men with greater 
receptor sensitivity usually have low normal serum testosterone levels 
whereas those with reduced AR sensitivity have levels in the upper 
normal range. he circulating levels of testosterone in turn are controlled 
by feedback on the hypothalamic–pituitary axis. he implications of 
this will be discussed further in the manuscript. Total testosterone 
in the circulation comprises free, albumin‑bound, and sex hormone 
binding globulin (SHBG)‑bound testosterone. he biologically available 
active hormone component is thought to be the sum of the free and 
albumin‑bound testosterone (bioavailable testosterone) as testosterone 
bound to SHBG is tightly bound and dissociates slowly and is therefore 
considered to be relatively inactive.
ANGINA AND CARDIAC ISCHEMIA
RCTs of testosterone treatment in men with cardiac ischemia
A case series (published in 1946) that combined several case reports 
found that testosterone therapy improved or abolished symptomatic 
angina chest pain in the majority of patients treated.7 However, the 
irst randomized placebo‑controlled trial using testosterone therapy 
in men with proven exercise‑induced cardiac ischemia was reported in 
1977.8 Postexercise ST segment depression was assessed as the sum of 
measurements taken from electrocardiogram (ECG) leads II, V4–V6 
at baseline and 2, 4, and 6 min of exercise. he sum of ST depression 
was reduced by 31.7% after 4  weeks’ therapy with testosterone 
cypionate (200 mg intramuscular injection [i.m.] weekly) and by 51.2% 
ater 8 weeks. At 1 month, a placebo‑controlled crossover study with 
oral testosterone reported a 77.4% reduction in angina symptoms, 
68.4% improvement in cardiac ischemia on a standard ECG, and 75% 
on an ECG Holter recording.9
In a definitive RCT, men with chronic stable angina already 
treated with two or more anti‑angina medications and unselected 
for testosterone deficiency  (mean total testosterone active 
group 13.55 ± 0.78 nmol l−1, placebo 12.38 ± 0.72 nmol l−1, P = 0.3) 
were treated with a daily 5 mg testosterone patch or placebo to achieve 
total testosterone (TT) in mid‑normal physiological range (18.57 ± 1.6 
nmol l−1) which demonstrated cardiac improvements.10 No signiicant 
change in estradiol was observed. Testosterone therapy led to a 
signiicant prolongation in exercise‑induced time to 1 mm ST segment 
depression ater 1 month, which was further improved ater 3 months. 
he lower the baseline serum testosterone, the greater the response to 
testosterone therapy in reduction in exercise‑induced cardiac ischemia. 
his inding was supported by a subsequent RCT that recruited men 
with angina and low testosterone (mean baseline TT 4.2 ± 0.5 nmol 
l−1) replaced to normal physiological levels.11 he beneicial efect of 
testosterone on cardiac ischemia persists for at least 12 months with no 
evidence of tachyphylaxis (baseline TT 9.9 ± 2.2 nmol l−1 replaced to 
the normal range by depot testosterone undecanoate, which increased 
by TT 9.2 + 8.5 nmol l−1).12 Supportive evidence has been provided 
by more recent RCT of elderly men with type 2 diabetes and proven 
CVD (n = 85) using oral testosterone undecanoate over 12 weeks. here 
was a reduction in the frequency of angina episodes and a decrease 
in the number of daily ischemic episodes and total ischemic burden 
using an ambulatory ECG recording.13 A smaller 2‑month RCT with 
crossover design (n = 25) again using oral testosterone undecanoate did 
not detect any increase in overall myocardial perfusion using magnetic 
resonance imaging (MRI) but did report that coronary arteries without 
stenosis had increased vascular perfusion.14
he potential mechanisms by which chronic testosterone therapy 
improves cardiac ischemia include enhancement of coronary blood low, 
increased red cell hemoglobin concentration, and enhanced myocardial 
function. Two studies have reported that administration of intravenous 
testosterone just prior to exercise treadmill testing demonstrated an 
acute efect on reduction in cardiac ischemia.15–17 Administration of 
testosterone  (including physiological concentrations) directly into 
unobstructed (<50% stenosis) coronary arteries at angiography, in men 
with proven coronary artery disease, which had been preconstricted 
with acetylcholine, resulted in a rapid (within 2–3 min) vasodilation and 
increase in coronary blood low.18 his inding provides key evidence for 
an acute vasodilator action of testosterone on the coronary vasculature 
that excludes the chronic efects that may occur in prolonged treatment, 
but pharmacological doses of testosterone were used.
Mechanisms of action of testosterone efects on vasoreactivity
he clinical trials demonstrate that testosterone has acute and chronic 
responses on exercise‑induced cardiac ischemia. he rapid‑onset 
efect on vasodilatation within a few minutes implies a nongenomic 
action. he inding that the beneit on exercise‑induced ischemia 
improves with time over  3  months suggests that testosterone has 
additional actions which could be mediated through genomic as well 
as nongenomic mechanisms. Furthermore, the efect of testosterone 
on exercise‑induced cardiac ischemia inversely correlates with baseline 
testosterone. his suggests that coronary arteries are more sensitive 
to testosterone in men with greater degree of testosterone deiciency.
Laboratory studies on isolated vessels using wire and perfusion 
myography have shown that testosterone has a direct rapid efect on 
rat, rabbit, and porcine preconstricted isolated coronary arteries.1,19,20 
Testosterone has also been found to dilate arteries from systemic 
arteries (radial, iliac, subcutaneous gluteal, mammary, and prostatic) 
and other vascular beds (pulmonary and mesenteric).1 his efect is 
independent of the vascular endothelium and is a direct efect on the 
vascular smooth muscle membrane.1 High‑dose concentrations are 
necessary to induce the vasoactive efects of testosterone in isolated 
vessels. Although this is a limitation on whether or not the vasoactive 
efect is physiological and/or pharmacological, it is well recognized 
that established vasoactive agents in  vivo such as noradrenaline, 
acetylcholine, and chromokalin  (a potassium channel opener) all 
require supraphysiological concentrations in vitro.21 Moreover, these 
efects are supported by evidence that direct actions of testosterone on 
ion channels occur at physiological concentrations.22,23
Studies have shown that testosterone acts as a calcium channel 
blocker and also stimulates potassium channel opening in vascular 
smooth muscle.1,24 Testosterone in single‑cell patch clamping studies 
inactivates L‑calcium channels in rat vascular smooth muscle cells 
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and human embryonic renal cells  (HEK293) transfected with the 
α1C‑subunit of the L‑calcium channel that forms the channel 
pore.22,23,25 Clinically used L‑calcium channel blockers (e.g., nifedipine, 
amlodipine) bind to a speciic site on α1C‑subunit to mediate their 
inhibitory efect. HEK293 cells, which have been transfected with a 
deactivating point mutation within the nifedipine‑binding site, lose 
the ability to respond to testosterone.25 his work clearly demonstrates 
that testosterone is an L‑calcium channel blocker, which mediates in 
part the vasodilator action. Furthermore, testosterone has been found 
to inhibit receptor‑operated calcium and intracellular store‑operated 
calcium channels that result in reduced cytosolic calcium concentration 
and smooth muscle relaxation.1,24
here are also experimental data that testosterone has a potassium 
channel opening efect that would induce arterial vasodilation.1,24 
Testosterone stimulation of potassium channel activation has been 
reported in animal coronary arteries as well as other systemic and 
mesenteric vessels. he efect of testosterone on vascular reactivity 
is complex and may difer between arteries. hese diferences in 
efect may have actions that inluence arterial tone during certain 
physiological situations.
A human study examined the effect of testosterone therapy 
on vascular reactivity in isolated human subcutaneous arteries.21 
This study compared the effect of chronic testosterone therapy 
on isolated subcutaneous resistance gluteal arteries taken before 
and 3 months after high‑dose testosterone treatment in men with 
chronic heart failure. The effect of testosterone on isolated gluteal 
vessels before testosterone therapy was also compared with gluteal 
vessels from a group of healthy eugonadal men. Testosterone 
induced significant vasorelaxation in constricted gluteal vessels 
from men with CHF with low serum testosterone concentrations 
compared to healthy controls and men with CHF and normal 
serum testosterone concentrations. After 3  months’ testosterone 
replacement in the hypogonadal subgroup, the vascular reactivity 
to testosterone in the isolated vessels became equivalent to the 
response observed in healthy and eugonadal men with heart failure. 
Importantly after testosterone therapy, the vasoconstrictor effect 
of noradrenaline increased and reduced the vasodilator response 
to acetylcholine and sodium nitroprusside (which breaks down to 
nitric oxide in the circulation). This effect physiologically would 
divert blood flow toward the vital organs, an important survival 
effect in chronic heart failure.
Testosterone is converted by aromatase to estradiol, which is a 
known vasoactive hormone. Estradiol mediates its vasoactive efects 
through stimulation of nitric oxide production. here is evidence 
from some studies that testosterone can stimulate the expression of 
nitric oxide synthase, which in turn would increase the capacity for 
greater nitric oxide release. However, it is not known whether this 
is a direct efect of testosterone or an indirect efect via estrogen.1 
Testosterone‑stimulated nitric oxide is known to promote cyclic 
guanosine monophosphate  (cGMP) release. cGMP is important in 
the vasorelaxation of vascular smooth muscle in the induction and 
maintenance of the penile erection.26 his efect might be tissue speciic, 
but efects of testosterone induction of tissue nitric oxide might have 
a role in other tissues.
CHRONIC HEART FAILURE
RCTs of testosterone treatment in men with CHF
Chronic heart failure  (CHF) is a common clinical condition 
associated with high morbidity and mortality rates and a 5‑year 
survival that is worse than many common cancers.27 Low serum 
testosterone concentrations are common in men with CHF and 
might contribute to the degree of cardiac dysfunction and cachexia. 
he acute and chronic efects of testosterone therapy in CHF have 
been investigated by RCTs.
he efect of acute testosterone administration has been studied 
in one RCT in men (n = 12) with moderate‑to‑severe let ventricular 
dysfunction with a mean total testosterone level of 14.1 nmol l−1 
(normal range: 7.5–37 nmol l−1).2 Patients were admitted to hospital 
for 2 days receiving placebo or testosterone (60 mg buccal tablet) 
and hemodynamic measurements were assessed by balloon lotation 
catheter inserted into the pulmonary circulation and cardiac output 
was measured by thermo‑dilution technique. Pulmonary capillary 
wedge pressure, pulmonary artery pressure, systemic vascular 
resistance as well as cardiac output were measured over 8 h. he two 
key indings of this study are that testosterone reduced the peripheral 
vascular resistance and improved the cardiac output. hese indings 
support a rapid‑onset efect of testosterone on reducing peripheral 
vascular tone. he absence of an acute improvement in pulmonary 
wedge pressure suggests that the reduction in peripheral vascular 
resistance is the major contributor to improved let ventricular 
function. Direct efects of testosterone on cardiac myocytes such 
as improved vascular blood low and glucose utilization may also 
be involved.
RCTs in men with CHF have used low doses of testosterone 
to avoid overtreatment as high dosages of anabolic‑androgenic 
steroids can cause myocardial stifening and hypertrophy.28 he irst 
RCT used intramuscular combined testosterone esters  (Sustanon®) 
100 mg every 2 weeks for 12 weeks in men (n = 20) with moderate 
heart failure (ventricular ejection fraction 35%).29 his study was the 
irst to report an improvement in functional exercise capacity that 
was associated with a beneicial efect on symptoms assessed by the 
Minnesota Living with Heart Failure questionnaire.29
In a larger  (n  =  76) and greater duration  (12‑month) study, 
men with chronic heart failure with a mean ventricular ejection 
fraction of 32.5% were randomized to testosterone 5  mg patch 
or placebo.30 Functional exercise capacity, as assessed using the 
incremental shuttle walk test  (which correlates with VO
2max
),
 
signiicantly improved from baseline in the testosterone‑treated 
patients but declined in the placebo group. Serial echocardiography 
demonstrated a signiicant increase in let ventricular length with 
testosterone treatment that correlates with the eiciency of cardiac 
output. In cardiac failure, the heart becomes more globular with 
reduced let ventricular length and eicacy  (Starling’s law of the 
heart). his study also showed that there was a trend to reduction 
in let ventricular mass. Importantly, mean blood pressure was 
maintained in the treated patients but declined in the placebo 
group. he worsening of blood pressure and of ventricular ejection 
fraction indicated worsening heart failure in the placebo‑treated 
group. 30 Supporting information from this study that testosterone 
has a beneicial efect on cardiac function was evidence that there 
was a signiicant improvement in New York Heart Association Class 
score of heart failure in 33% of patients. Furthermore, a greater 
increase in serum testosterone level correlated with a greater beneit 
on functional exercise capacity. Hand grip strength also improved 
in the dominant hand, a inding suggesting that improved overall 
skeletal muscle strength might contribute to the observed improved 
exercise capacity. here was no excess of serious adverse events in 
the testosterone‑treated patients, and it is important to recognize 
that the beneicial efects in this trial occurred with a small increase 
in total testosterone of only 6 nmol l−1.
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The beneficial effects of testosterone in CHF were confirmed by 
a 12‑week study of seventy men with CHF (NYHA II or II with a left 
ventricular ejection fraction of <40%).31 The patients received either 
intramuscular depot testosterone undecanoate or placebo. The 
testosterone‑treated group had significant improvements compared 
to placebo in the 6‑min walk test and VO
2max
. This trial also found 
that testosterone therapy improved the vagal nerve‑mediated 
arterial baroreceptor cardiac reflex sensitivity  (BRS), a reflex 
which is known to be suppressed in CHF and is associated with a 
poor prognosis.
 
In another RCT (n = 50) with CHF,
 
testosterone 
therapy over  12  weeks resulted in significant improvement in 
diastolic function, distance traveled in the 6‑min walk test, and 
quality‑of‑life scores.32
Mechanisms of action of testosterone efects in CHF
Chronic heart failure is associated with adaptive changes in vascular 
tone of the circulation, increasing peripheral vasoconstriction. 
his response is mediated initially by acute changes in systemic 
neurovascular hormones, mainly noradrenaline and adrenaline, which 
persist in chronic heart failure and cause adverse efects on cardiac 
function in the long term.33 CHF is also associated with a decrease in 
baroreceptor sensitivity.33 Arterial baroreceptors, which are mainly 
situated in the carotid sinuses and aortic arch and are supplied by the 
vagus nerve, are important stretch sensors of arterial wall pressure 
changes. he most common cause of cardiac failure and impaired 
let ventricular dysfunction is coronary artery disease with resultant 
cardiac ischemia leading to diminished cardiac muscle contractility 
and weakness. Systemic efects of cardiac failure include fatigue, 
lethargy, and breathlessness but also a chronic inlammatory state, 
insulin resistance, and an anabolic–catabolic imbalance, eventually 
leading to cardiac cachexia. Loss of muscle mass aggravates the 
symptoms of CHF leading to increasing weakness and decreasing 
exercise capacity.
Low testosterone concentrations are common in men with 
CHF and are associated with an increased mortality. Testosterone 
deficiency might contribute to the morbidity of CHF because 
testosterone deiciency is associated with reduced cardiac function, 
loss of lean muscle mass and strength, chronic anemia, and insulin 
resistance.34,35 Testosterone treatment therefore might improve 
the symptoms of CHF through several potential mechanisms 
(summarized in Figure  1). First, the acute efect of testosterone 
in reducing peripheral vascular resistance leads to an increased 
cardiac output.2 It is not clear, however, that this efect is maintained 
over longer time periods. Second, testosterone‑induced coronary 
vasodilation may improve blood low to ischemic areas of the cardiac 
muscle, enhancing contraction. hird, it is known from in  vitro 
studies that testosterone is an arterial and venous dilator which could 
potentially in vivo reduce pulmonary vessel pressure, reducing the 
preload pressure on the right side of the heart.1 his however was not 
observed in the study when testosterone was acutely administered to 
men with chronic heart failure in terms of a reduction in pulmonary 
capillary wedge pressure.2
Testosterone replacement in men with CHF enhances carotid 
sinus baroreceptor sensitivity.31 here is evidence that this action 
of testosterone may be mediated at the level of the brain stem as 
androgen receptor blockade inhibits baroreceptor responses.36 
Furthermore, androgen receptors have been detected in neurons in 
the brain stem which are known to be involved in blood pressure 
control.37 This study also detected reduction in the gradient of 
ventilation to carbon dioxide output (VE/VCO
2
 slope) and an increase 
in peak VO
2
 and peak workload on testosterone therapy. he VE/
VCO
2
 slope relects the increase in ventilation in response to CO
2
 
production and correlates with ventilator drive. he greater the VE/
VO
2
 slope, there is an increased risk of a major cardiac event. his 
speciic efect on improved ventilation provides convincing evidence 
that this is a direct action of testosterone, which would contribute to 
the beneit on functional exercise capacity observed in all the RCTs 
described above.
Chronic anemia is common in men with CHF and an increase 
in hematocrit may improve the symptoms of CHF. Testosterone 
replacement can result in small rises in hemoglobin and hematocrit 
which have been detected in one study but not in the others.30 Brain 
natriuretic peptide is a marker of the degree of heart failure. A trend 
toward lowering brain natriuretic peptide levels was found in one 
study, but this may have been underpowered to show a signiicant 
change.29
CHF is associated with reduced muscle mass and atrophy, 
which affects a greater proportion of type  II muscle fibres.38,39 It 
has been demonstrated in men with CHF that decreasing serum 
testosterone levels correlate with worsening functional exercise 
capacity.35 Exercise training in men with CHF can improve muscle 
structure and function and the degree of ventilation.40 The trials 
of testosterone therapy have shown an increase in dominant but 
not nondominant hand grip strength but no evidence of muscle 
bulk as assessed by CT scanning of mid‑thigh and mid‑calf after 
3 months and 12 months.28,29 Maximal voluntary contraction of the 
quadriceps and an increase in peak torque significantly increased 
in another trial.31 This evidence overall shows that there may 
be a beneficial effect on muscle function, which is likely to be a 
contributory component to the reported improvement in functional 
exercise capacity.
CHF induces a state of chronic inflammation and insulin 
resistance that play a role in cardiac cachexia and could be important 
factors that impair skeletal muscle function and contribute to muscle 
atrophy.41–43 Tumor necrosis factor‑α (TNF‑α), interleukin‑1 (IL‑1), 
and interleukin‑6 (IL‑6) are elevated in men with CHF.41 hese speciic 
cytokines have all been shown to induce insulin resistance and have a 
major role in the efects of cachexia. Testosterone replacement therapy 
in men with cardiovascular disease suppresses circulating levels of 
TNF‑α, which has also been implicated in CHF.44 However, TNF‑α 
was not suppressed over 3 months of testosterone treatment in men 
with CHF.45
There is some evidence that testosterone replacement therapy 
improves insulin sensitivity in states of insulin resistance in men 
with CHF and metabolic syndrome or type  2 diabetes.31,46,47 The 
positive effect of testosterone on insulin resistance in CHF was 
demonstrated in a double‑blind randomized placebo‑controlled 
crossover trial over  3  months with patients randomized to 
testosterone (Sustanon® 250) or placebo for 4  weeks, and then 
a 4‑week washout period followed by the opposite therapy.47 
Testosterone treatment significantly increased insulin sensitivity 
and reduced fasting glucose. There was no significant difference in 
glucose utilization or insulin release between treated and placebo 
groups in response to a standard glucose tolerance test.47 This 
effect of testosterone on reducing insulin resistance was confirmed 
in a subsequent study, but fasting glucose was not reported.31 
Testosterone therapy also resulted in a small but significant 
reduction in body fat percentage.31
These findings collectively demonstrate that the effects of 
testosterone in men with CHF have multifactorial effects on 
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diferent systems and organs which all contribute independently to 
the clinical diferences observed in improved cardiac and exercise 
function (Table 1 and Figure 1).
CARDIAC ELECTROPHYSIOLOGY
RCTs of the efects of testosterone therapy on cardiac electrophysiology
The main effect of testosterone on the electrocardiogram is on the 
QT
c 
interval, which is a standardization value, which compensates 
for variability in the QT due to changes in heart rate. It is known 
that men have a shorter QT
c
 than women, a difference that is not 
present before puberty.48 The Third National Health and Nutrition 
Examination Survey  (NHANES) and the Multi‑ethnic Study of 
Atherosclerosis reported that there was an inverse relationship 
between QT‑interval duration and testosterone levels in men.49 
Evidence also demonstrates that men with hypogonadism, 
including men with obesity‑related hypogonadism, have prolonged 
QT
c
 intervals.50,51 The clinical importance of a prolonged QT
c
 is 
its association with an increased risk for ventricular tachycardia, 
ventricular fibrillation and torsades de points which can all cause 
sudden death.
Testosterone therapy at physiological dosages was reported to 
reduce QT dispersion (maximum QT – minimum QT interval) in a 
combined analysis of two RCTs of men with chronic stable angina and 
congestive cardiac failure, respectively.3 A subsequent RCT of thirty 
men with chronic cardiac failure found that testosterone therapy also 
shortened the QT and QT
c 
intervals.4
Mechanisms of action of testosterone efects in cardiac electrophysiology
A n  a n i m a l  s t u d y  c o m p a r e d  Q T
c
 i n t e r v a l  b e t w e e n 
orchidectomized testosterone‑replaced and orchidectomized 
testosterone‑nonreplaced mice.52 Testosterone replacement 
significantly decreased ventricular repolarization by increasing 
the ultra‑rapid potassium current, I (Kur), in isolated ventricular 
cardiac myocytes using whole cell voltage and current clamps. 
I  (Kur), which is the major current involved in cardiac myocyte 
repolarization, is mediated by the Kv1.5 potassium channel. 
This study also demonstrated that testosterone increased protein 
expression of the Kv1.5 potassium channel. Another study found 
that testosterone correlated inversely with action potential duration 
and the risk of early after depolarizations in female rabbits.53 A 
greater percentage of early after depolarizations is associated with 
an increased risk of arrhythmia.54 These basic science experimental 
findings, although limited in number, support evidence from 
clinical trials for a potentially important role of testosterone as 
an anti‑arrhythmic agent. It is also known that testosterone levels 
fall acutely after myocardial infarction and these studies raise the 
question as to whether or not low testosterone may increase the 
risk of post‑myocardial infarction arrhythmias.55
Figure 1: Putative beneficial effects of testosterone on heart failure. Evidence from multiple clinical, experimental, and mechanistic studies suggests potential 
beneficial testosterone actions on heart failure.
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EFFECTS OF TESTOSTERONE THERAPY ON 
CARDIOVASCULAR RISK AND ATHEROSCLEROSIS
Modifiable cardiovascular risk factors for myocardial infarction 
include diabetes  (insulin resistance),  abdominal obesity, 
hypertension, dyslipidemia, smoking, reduced physical activity, 
reduced daily fruit and vegetable consumption, regular alcohol 
consumption, and stress.56 Testosterone deficiency in men is 
associated with insulin resistance  (type  2 diabetes), abdominal 
obesity, hypertension, and dyslipidemia as well as lack of physical 
activity.46,57 In most but not all studies, RCTs using testosterone 
replacement therapy have shown to improve insulin resistance, 
glycemic control, visceral adiposity, and cholesterol  (Table  1).58 
Levels of HDL‑cholesterol may fall, remain unchanged, or rise with 
testosterone replacement.
Insulin resistance and glycemic control
Insulin resistance is the major biochemical abnormality in men 
with metabolic syndrome or type  2 diabetes and is considered 
to be an intermediary cardiovascular risk factor that promotes 
hyperglycemia, dyslipidemia, hypertension, and endothelial 
dysfunction. In the presence of significant insulin resistance, 
testosterone replacement therapy increases insulin sensitivity. This 
effect is evident after 3 months’ treatment and maintained for at 
least up to 12 months.59–64 Initial trials measured insulin resistance 
using homeostatic mechanism of insulin resistance (HOMA‑IR). 
A  12‑month study showed that testosterone improved insulin 
sensitivity by 15%, an effect that is equivalent to that observed by 
metformin usage, a mainstay of management in type 2 diabetes.62 
One study did not show a change in HOMA‑IR; however, the 
baseline mean HOMA‑IR was in the normal insulin sensitivity 
range.65 These findings have been subsequently confirmed using 
hyperinsulinemic euglycemic clamp studies which confirmed that 
testosterone therapy increased the glucose disposal rate as well as 
reducing HOMA‑IR.64
Glycated hemoglobin (HbA1c) measurement is universally used in 
patients with diabetes for the assessment of glycemic control. he studies 
above have either shown a small but signiicant reduction in HbA1c 
or no efect. A meta‑analysis of RCTs did not demonstrate an overall 
change in HbA1c but this has to be taken into context that no study 
exclusively had been performed on men with poor control.66 In small 
studies including men with good control and not statistically powered 
for HbA1c improvement, it would be unlikely to observe a beneit. 
Clinical trials of new drugs for diabetes usually require large numbers 
with the study conined to men with HbA1c levels ≥6.5% or 7%, and 
the current trials may not have been of suicient duration to detect a 
change and included men with good control. On this basis from RCTs, 
it is not known whether or not testosterone replacement has a positive 
efect on glycemic control. However, some studies have demonstrated 
that there is an improvement in HbA1c59,62,63 and fasting glucose.59,64
Dyslipidemia
he response of serum lipid parameters to testosterone replacement 
in trials has been mixed. Speciically, total cholesterol and low‑density 
lipoprotein‑cholesterol  (LDL‑C) fall by between 5% and 14% from 
baseline in studies involving healthy men and men with CVD, 
metabolic syndrome, and type 2 diabetes.11,13,44,59,62,63,67,68 However, some 
studies have shown no response at all.67,68 he diferences between 
formulations used, whether or not adequate testosterone levels were 
attained, age of population, statin therapy, and duration of the study 
may afect the result.
HDL‑cholesterol also may rise, fall, or elicit no change in levels.67–69 
HDL‑cholesterol ater an initial decrease can return to baseline ater 
prolonged replacement. One hypothesis is that testosterone first 
stimulates the reverse transport of excess cholesterol from peripheral 
tissues to the liver for excretion. his depletes the HDL‑cholesterol pool 
before it recovers ater stabilization of the body’s cholesterol balance.
he majority of RCTs have not identiied a signiicant change in 
triglycerides.68 Lowering of fasting triglycerides has been evident in 
trials using the long‑acting depot testosterone undecanoate (reference). 
Lipoprotein  (a), a strong predictor for the future development of 
atherosclerosis, decreased in one trial of testosterone therapy by 
approximately 25%.62 he clinical efect of this change is not known but 
potentially could be an important factor in reducing the development 
of CVD.
Body composition
RCTs of testosterone replacement therapy in hypogonadal men 
consistently report an increase in lean body mass and a decrease 
in percentage fat mass which is independent of the formulation of 
testosterone used in the study.70 he majority of the studies also found 
a reduction in waist circumference, which correlates positively with 
Table 1: Summary of effects of testosterone therapy on cardiovascular 
parameters
Parameter Condition Treatment effect
Exercise-induced 
ischemia
Chronic stable angina ↑ Time to 1 mm ST depression
Myocardial 
perfusion
CAD ↑ Perfusion of coronary 
territories with no stenosis
Coronary artery 
blood flow
Coronary angiography ↑ Blood flow and artery 
diameter
Functional exercise 
capacity
CHF ↑ Distance (shuttle walk/6-min 
walk tests)
VO
2max
CHF ↑ VO
2max
BRS CHF ↑ Carotid baroreceptor 
sensitivity
LV length CHF Maintained compared to ↓ 
placebo
Blood pressure CHF Maintained compared to ↓ 
placebo
NYHA CHF Improved class in 30%
Q-T interval CAD, CHF ↓ QT, QT
c
Body composition CAD, T2D ↓ Percentage fat mass, ↑ lean 
mass, ↓ WC
Cholesterol CAD, T2D ↓ Total-C, ↓ LDL-C (some 
studies)
HDL-C CAD, T2D Different responses ↓, ↔, ↑ 
HDL-C
Triglycerides CAD, T2D No response
Insulin resistance T2D, CHF ↓ Insulin resistance (majority 
confirmed by clamp studies)
HbA1c T2D ↔ (unselected for poor 
control)
Fasting glucose CHF, T2D ↓ CHF, ↔ or ↓ T2D
TNF-α CAD, CHF ↓ CAD or ↔ CHF, CAD
IL-10 CAD ↑
tPA/PAI-1/
fibrinogen
CAD ↔
BRS: baroreceptor cardiac reflex sensitivity; LV: left ventricular; NYHA: New York Heart 
Association; HDL-C: high-density lipoprotein-cholesterol; HbA1c: glycated hemoglobin; 
TNF-α: tumor necrosis factor-α; IL-10: interleukin-10; tPA: tissue plasminogen activator; 
PAI-1: plasminogen activator inhibitor-1; CAD: coronary artery disease; CHF: chronic 
heart failure; T2D type 2 diabetes; WC: waist circumference; LDL-C: low-density 
lipoprotein-cholesterol; VO
2max
: maximum oxygen consumption; ↑: increase; ↓: decrease;  
↔: no significant change
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visceral adiposity.70 Reductions in body weight may not be initially 
evident as the gain in lean mass balances out the fat loss which occurs.60 
In addition, the studies published are between 3 and 12  months 
and may not be of suicient length to detect changes. Serum leptin, 
which positively correlates with fat mass, falls with testosterone 
replacement.59,60 A registry study has demonstrated reduction in weight 
that continues for at least 8 years on testosterone replacement.71
Inlammation
Atherosclerosis is associated with a chronic inlammatory state that 
is relected in the elevation of circulating cytokines. Some trials have 
recorded a suppression of TNF‑α, whereas others have not.11,44,45,60 Serum 
interleukin‑1β and C‑reactive protein decreased with testosterone in 
one study but this has not been conirmed in other trials. 60,64 Serum 
interleukin‑10, an anti‑inlammatory and anti‑atherogenic cytokine, 
increases in response to testosterone therapy.44 In one study of men with 
diabetes mellitus and low serum testosterone, testosterone replacement 
decreased serum adiponectin but did not cause signiicant changes in 
serum IL‑β, IL‑6, or hs‑CRP. 72 In two subsequent RCTs of testosterone 
replacement, one in men with metabolic syndrome and the second in 
men with type 2 diabetes, suppressed TNF‑α, IL‑1β, and hs‑CRP. 60,64 
It is recognized that testosterone has immunomodulatory actions but 
it is not clear how this relates directly to atherosclerosis in vivo as this 
has not been investigated.1
Coagulation
Only two RCTs have studied the efect of testosterone on coagulation. 
hese trials did not detect any efect on plasma ibrinogen, factor 
VII, plasminogen activator inhibitor‑1 activity, or tissue plasminogen 
activator activity.14,73
Hepatic steatosis
Hepatic steatosis is associated with an increased risk of cardiovascular 
disease.74 An 18‑week RCT of testosterone undecanoate  (depot 
intramuscular injection) against placebo in hypogonadal men (n = 67) 
with obesity and severe obstructive sleep apnea found a signiicant 
reduction in hepatic fat as assessed by computed tomography (CT) 
scanning.75 his change was associated with increased insulin sensitivity 
and increased muscle mass. No changes in body composition with 
regard to fat deposits were identiied; however, the study may not have 
been of suicient duration.
ATHEROSCLEROSIS
here is no deinitive RCTs of testosterone replacement therapy that 
report direct efects on atherosclerosis, plaque stability, or disease 
progression or amelioration. Carotid intimal media thickness (CIMT) 
is considered to be a surrogate marker of the degree of atherosclerosis. 
A small RCT over 12 months which evaluated the efect of testosterone 
on CIMT as well as angina reported a trend to an improvement in 
this measurement although this study was underpowered.12 A second 
trial using testosterone undecanoate found that there was a signiicant 
reduction in CIMT in the treated group and a reduction in highly 
sensitive CRP over a 24‑month period in men with metabolic syndrome 
and late‑onset hypogonadism (n = 50, randomized at 4:1 on treatment 
to placebo).61 An adequately powered RCT (TEAAM trial) that studied 
the efect of testosterone gel therapy against placebo over 3 years did not 
detect any changes in either CIMT or coronary artery calcium scores.76 
Participants (n = 306) were randomized of which 211 completed the 
study with all participants included in the primary analysis. he study 
group (mean age: 67.6 years) consisted of 15% with cardiovascular 
disease, 15% with diabetes, 42% with hypertension, and 27% with 
obesity. he study has some limitations, including that patients did 
not speciically have to have hypogonadism (testosterone deiciency) 
but just a serum testosterone <400 ng dl−1 (13.9 nmol l−1). Statin use 
in the study was high and may be a confounding factor. here were 
no signiicant diferences in cardiovascular events between the study 
groups, but the results of the study cannot be extrapolated to give any 
clinical guidance on the risk of future major adverse cardiac events 
(MACE) related to testosterone therapy.
A more recent large  (n  =  138 completers) 12‑month RCT of 
hypogonadal men >65 years examined the efect of testosterone on 
coronary artery plaque volume.77 Testosterone treatment was associated 
with a greater increase in noncalciied plaque volume. he clinical 
inference from this change is unclear. here was no change in the 
coronary artery calcium score between the groups. An exploratory 
analysis of plaque components found that testosterone therapy 
signiicantly increased the ibrous plaque volume compared to placebo. 
he changes in noncalciied coronary artery plaque volume were not 
associated with changes in the levels of total testosterone as a result of 
treatment. An increase in plaque size alone may not be associated with 
an increased risk of MACEs as the plaque content, stabilization, and risk 
of rupture might be more important to clinical outcomes. Testosterone 
in the short term could possibly promote a “healing response” within 
the plaque delivering a more stable plaque, as has been shown for 
statin therapy, and may result initially in an increase in plaque volume.
MECHANISMS OF ACTION OF TESTOSTERONE EFFECTS ON 
CARDIOVASCULAR RISK FACTORS AND ATHEROSCLEROSIS
Insulin resistance is associated with impairment of glucose utilization, 
which includes glucose uptake and metabolism by cells. he three 
major tissues that account for whole‑body insulin resistance are 
muscle, liver, and fat. Seventy percentage of reduced insulin sensitivity 
is accounted for by striated muscle. he key glucose uptake transporters 
are the GLUT transporter family, with GLUT4 being the predominant 
transporter in muscle and adipose tissues. Insulin stimulates glucose 
uptake by increasing the translocation of GLUT4 transporters from 
the cytosol to the cell membrane. In the liver, the mechanism for 
insulin‑stimulated uptake of glucose is less clear. Hepatocytes express 
the insulin‑independent bidirectional GLUT2 transporter.
In a hyperinsulinemic euglycemic clamp RCT of testosterone 
replacement therapy, eugonadal hypogonadal men with type 2 diabetes 
had reduced baseline subcutaneous adipose tissue mRNA expression 
of the insulin receptor‑β (IR‑β), insulin receptor substrate‑1 (IRS‑1), 
Akt‑2 (involved in IR‑β downstream signal transduction), and GLUT4 
and protein expression of IR‑β and Akt when compared to eugonadal 
men with type 2 diabetes.64 Testosterone replacement ater 24 weeks 
signiicantly increased mRNA expression in hypogonadal men with 
type 2 diabetes of IR‑β, IRS‑1, Akt‑2, and GLUT4.62
Testosterone has been shown to stimulate IRS‑1, IRS‑2, Akt, 
glucose uptake, and GLUT4 translocation in adipocytes and striated 
muscle.78–82 Importantly, testosterone increases GLUT4‑dependent 
glucose uptake in cardiomyocytes.83 Testosterone has also been shown 
to increase the expression of the key regulatory enzymes of glycolysis, 
hexokinase (glucokinase in the liver), and phosphofructokinase, which 
impacts on the rate of this pathway.78,82 Recent evidence has reported 
that testosterone produced a rapid nongenomic action promoting the 
activation of Akt, Erk, and mTOR, all factors involved in downstream 
insulin receptor stimulation.84
Testosterone in animal and cell culture studies has also been 
demonstrated to alter lipid metabolism.78 Testosterone reduces de novo 
lipogenesis in adipose and liver tissue as well as regulating free fatty 
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acid and triglyceride uptake into subcutaneous fat depots.78 Lipoprotein 
lipase (LPL) is an extracellular enzyme on the surface of adipocytes, 
which converts triglycerides into free fatty acids for uptake into the 
cell for conversion back into triglycerides for storage.85 Testosterone 
inhibits LPL activity and therefore would reduce fatty acid uptake into 
tissues, but testosterone deiciency is associated with increased LPL 
resulting in enhanced uptake.78,86,87 here may be diferences between 
tissues in the testosterone‑induced LPL activity, for example in mice, 
a low testosterone state is associated with an decreased LPL mRNA 
expression in subcutaneous but not in visceral fat.82
Testosterone deficiency is also associated with increased fat 
deposition in the liver, which in animal studies has led to the 
development of marked hepatic steatosis.88 Testosterone has also 
been shown to suppress de novo lipogenesis in the liver and protect 
against hepatic steatosis in testosterone‑deicient mice.89 Testosterone 
replacement reduced mRNA and protein expression of acetyl CoA 
carboxylase and fatty acid synthase, the two regulatory enzymes of 
fatty acid synthesis.89
Glucose in the circulation that cannot be metabolized for energy 
production under normal physiological conditions is stored as glycogen 
in liver and muscle or converted to lipids that are stored in subcutaneous 
adipose tissues. When there is excess lipid that cannot be removed from 
the circulation, this leads to an “overspill” of lipid into visceral fat, 
liver, and then other tissues including arterial walls, promoting the 
development of atherosclerosis (Figure 2).90 Testosterone deiciency as 
described above adversely afects carbohydrate and lipid metabolism, 
promoting fat accumulation in visceral adipose tissue, liver, and lipid 
streaks within the arterial walls. he increase in waist circumference 
as a measure of visceral adiposity has been observed in many clinical 
studies. A selective knockdown of the AR in adipocytes in mice causes 
visceral adiposity, insulin resistance, and hyperglycemia.91 his study 
demonstrates a key role of testosterone action on adipocyte metabolism 
which would impact on the body’s overall state of cardiometabolic 
function.
he changes in enzymes under conditions of low testosterone 
in subcutaneous fat suggest that there is an impairment of free fatty 
acid uptake and decreased expression of the GLUT4 transporter 
and reduced glucose uptake. Testosterone deiciency may result in 
a physiological state where the subcutanoeus fat uptake, acting as a 
'bufer' protecting against ectopic fat deposition is impaired, causing 
“overspill” of fat and deposition in visceral adipocytes, liver, and arterial 
walls, leading eventually to hepatic steatosis and atherosclerosis.78,89
he reason why testosterone replacement in some clinical trials 
produces a small fall in total and LDL‑cholesterol is not fully clear. 
Testosterone replacement in deicient mice increased the expression of 
mRNA and protein of the major cholesterol cellular elux transporter 
ABCA1, apo‑E lipoprotein, and a master regulator of cholesterol 
metabolism liver X receptor in liver and in subcutaneous adipose 
tissue.89 here is evidence that testosterone stimulates cholesterol elux 
from the THP‑1 monocyte‑macrophage cell line, which is associated 
with translocation of the ABCA‑1 transporter to the cell membrane.92
he efect on HDL‑cholesterol is not well understood at present. 
In both healthy men and men with type 2 diabetes, HDL‑cholesterol 
correlates positively with testosterone serum levels.93,94 HDL‑cholesterol 
is a cholesterol acceptor which transports cholesterol from peripheral 
tissues to the liver for excretion. In the initial stages of clearing 
excess cholesterol from the tissues, it has been hypothesized that 
HDL‑cholesterol is used up and metabolized, producing an initial 
small fall in levels which then recovers ater prolonged treatment.95 
his hypothesis, however, remains unproven.
Animal experiments have found that a state of testosterone 
deiciency promotes the development of lipid streak formation, the 
irst stage of atherosclerotic plaque, in the aortae of animals fed with a 
cholesterol‑rich diet.96–99 his efect is associated with the development 
of marked hepatic steatosis.89 he dominant cell type within the lipid 
streak has been identiied as macrophages. Testosterone substitution 
has been shown to protect and ameliorate against the development 
of the early plaques.96–99 he exact mechanism by which testosterone 
mediates these efects is not clear, but evidence suggests that both 
AR‑dependent and AR‑independent actions have a role.98,100 Potential 
mechanisms are reduction of lipid uptake into the arterial wall and 
an anti‑inlammatory efect directly at the level of the macrophage. 
Testosterone as described above suppresses serum pro‑inlammatory 
cytokines and promotes anti‑inflammatory actions. Testosterone 
speciically was found to inhibit the release of TNF‑α, IL‑1β, and IL6 
from cultured monocytes from hypogonadal men with type 2 diabetes 
(T2D).101
CARDIOVASCULAR EVENTS IN RCTS
here have been no adequately powered studies of testosterone 
replacement therapy which have been performed to assess whether 
or not there is an increase, decrease, or no efect on the incidence 
of MACE. A recent meta‑analysis of 39 RCTs and 10 observational 
studies did not identify any signiicant association of testosterone 
therapy with MACE events  (myocardial infarction, stroke, and 
mortality).102 No individual RCT where testosterone was replaced 
to the normal healthy range reported an increase in MACE. he 
duration of the trials ranged between 6  weeks and 3  years and 
included 5451 men (3230 received testosterone and 2221 placebo). 
here was no increased risk independently of myocardial infarction, 
stroke, or death.
No RCT which speciically studied men with known CVD and/or 
metabolic syndrome  ±  type  2 diabetes reported an increased risk 
of any cardiovascular event.8,10–14,21,29–32,59–65,102 he TOM trial was an 
RCT (6 months’ duration) which had a primary outcome of the efect 
of testosterone on muscle mass and strength in a frail cohort of elderly 
men with multiple comorbidities.103 he initiation of testosterone gel 
used twice (100 mg) the recommended licensed dose (50mg od), with 
six individuals titrated to three times the dose (150 mg). Although the 
study was not powered for the assessment of cardiovascular events, 
it was considered that there was an excess of cardiovascular‑related 
events in the treatment arm. hese events were not well documented, 
included self‑reported syncope, leg edema which is known to occur 
with over‑replaced testosterone treatment, and tests such as exercise 
treadmill ECG which could have been abnormal prior to the study, not 
being performed in patients before entry into the trial. he CV‑related 
events occurred mainly in those individuals on the higher testosterone 
doses. A similar 6‑month RCT examining the efect of testosterone 
therapy on muscle strength in intermediate‑frail and frail elderly men 
which used standard testosterone gel dose (50 mg od) reported no 
diferences in CV events compared with placebo.104
The clinical importance for men to have testosterone levels 
within the mid‑to‑upper normal healthy range is emphasized in the 
following studies. Men with endogenous testosterone levels within the 
mid‑to‑higher normal healthy range have the lowest rate of MACE.105 
Evidence from a large epidemiological study supports the meta‑analysis 
that normalization of testosterone within the mid‑normal range 
reduces MACE compared to men on testosterone replacement who 
have been undertreated.106
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CONCLUSIONS
RCTs conirm that testosterone does improve cardiac ischemia in men 
with chronic stable angina and functional exercise capacity and VO
2 max
 
in men with chronic heart failure. hese efects have been shown to 
persist for at least 1 year. hese indings are supported by mechanistic 
studies, which have shown that testosterone is a coronary vasodilator as 
well as actions on other arteries within the body. hese efects are acute 
as well as chronic with testosterone able to alter vascular responsiveness 
to established endogenous vasoactive agents including noradrenaline 
and acetylcholine. he efects of testosterone in chronic heart failure 
patients are probably a combination of efects on reducing peripheral 
vascular resistance, improved let ventricular function and efects on 
skeletal muscle strength, and general well‑being. Testosterone may 
have anti‑arrhythmic property with a documented efect on shortening 
the Q‑T interval, but there are no studies which have been powered 
adequately to determine if this action translates into a clinically relevant 
efect. he beneicial efects on these three clinical states appear to 
be primarily mediated via an AR‑independent action on L‑calcium 
channel blocking and potassium channel opening.
RCTs have consistently reported that testosterone replacement 
therapy reduces fat mass and increases lean mass. he majorities of 
trials have reported a reduction in waist circumference, but do not 
usually become statistically signiicant in most studies until ater 
12  months’ treatment. Long‑term registry studies report that the 
efect of testosterone on waist circumference and BMI shows that 
beneits gradually accrue over several years. Testosterone improves 
insulin resistance, but an efect on glycemic control is not yet clear 
as no RCTs have specifically examined the effect of testosterone 
replacement in hypogonadal men with uncontrolled diabetes which 
would be a standard study required for any new treatment for this 
condition. Scientiic studies have provided insight into the importance 
of testosterone in the regulation of carbohydrate and lipid metabolism, 
which provide support to a positive efect on metabolic pathways, which 
contribute to cardiovascular risk beneits. he efects of testosterone 
on reducing serum cholesterol are small, but the tissue‑speciic efects 
at the level of the plaque are unknown. Animal studies do provide 
evidence that testosterone can protect against the development of early 
stages of atherosclerosis, but it is not clear that this efect translates 
into humans. he RCTs which have examined the efect of testosterone 
replacement on CIMT and plaque calcium and volume have not 
demonstrated any convincing evidence for testosterone as having a 
beneicial or adverse efect on the plaque. he major limitation is not 
having a speciic technique, which can assess plaque stability in vivo 
which can be applied in large RCTs. he knowledge that testosterone 
replacement in men with type 2 diabetes and hypogonadism improves 
mortality does signify that the hormone does have an important role in 
health. he questions remain as to whether the actions of testosterone 
are involved with cardiovascular health protection and/or stabilization/
amelioration of established cardiovascular disease.
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